Drug intelligence / Profile preview

2'-O,4'-C-Spirocyclopropylene Bridged Nucleic Acid

Development stage: Unknown
Lead developer: Luxna Biotech
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

scpBNA is a modified nucleic acid analog that exhibits high binding affinity towards complementary RNA strands and increased enzymatic stability compared to natural and other modified nucleic acids. It is used in antisense oligonucleotides to improve therapeutic efficacy by enhancing stability and reducing hepatotoxicity when combined with other modifications like AmNA and PO linkages[1][2][5].

Other names: scpBNA

Beyond the preview

Go deeper on 2'-O,4'-C-Spirocyclopropylene Bridged Nucleic Acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2'-O,4'-C-Spirocyclopropylene Bridged Nucleic Acid.

Explore the full profile